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Abstract: In December 2019, the novel coronavirus disease pandemic (COVID-19) that 
began in China had infected so far more than 109,217,366 million individuals worldwide and 
accounted for more than 2,413,912 fatalities. With the dawn of this novel coronavirus 
(SARS-CoV-2), there was a requirement to select potential therapies that might effectively 
kill the virus, accelerate the recovery, or decrease the case fatality rate. Besides the currently 
available antiviral medications for human immunodeficiency virus (HIV) and hepatitis 
C virus (HCV), the chloroquine/hydroxychloroquine (CQ/HCQ) regimen with or without 
azithromycin has been repurposed in China and was recommended by the National Health 
Commission, China in mid-February 2020. By this time, the selection of this regimen was 
based on its efficacy against the previous SARS-CoV-1 virus and its potential to inhibit viral 
replication of the SARS-CoV-2 in vitro. There was a shortage of robust clinical proof about 
the effectiveness of this regimen against the novel SARS-CoV-2. Therefore, extensive 
research effort has been made by several researchers worldwide to investigate whether this 
regimen is safe and effective for the management of COVID-19. In this review, we provided 
a comprehensive overview of the CQ/HCQ regimen, summarizing data from in vitro studies 
and clinical trials for the protection against or the treatment of SARS-CoV-2. Despite the 
initial promising results from the in vitro studies and the widespread use of CQ/HCQ in 
clinical settings during the 1st wave of COVID-19, current data from well-designed rando-
mized controlled trials showed no evidence of benefit from CQ/HCQ supplementation for the 
treatment or prophylaxis against SARS-CoV-2 infection. Particularly, the two largest rando-
mized controlled trials to date (RECOVERY and WHO SOLIDARITY trials), both con-
firmed that CQ/HCQ regimen does not provide any clinical benefit for COVID-19 patients. 
Therefore, we do not recommend the use of this regimen in COVID-19 patients outside the 
context of clinical trials. 
Keywords: antiviral drugs, chloroquine, COVID-19, drug safety, hydroxychloroquine, 
SARS-CoV-2, treatments
Introduction
Coronavirus disease-2019 (COVID-19) is a disease pandemic caused by a new 
strain of coronavirus called severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2).1 Formerly, this disease was referred to as ‘2019 novel coronavirus’ 
or “2019-nCoV.” The virus name (SARS-CoV-2) was chosen because the virus is 
genetically related to the coronavirus responsible for the SARS outbreak of 2003.1 
While related, the two viruses are different.1 The spread of SARS-CoV-2 began in 
Wuhan, China, by the end of December 2019.2 As of February 17, 2020, the 
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COVID-19 pandemic has swept the world and infected 
more than 109,217,366 million individuals worldwide 
and accounted for more than 2,413,912 fatalities.2
The initial case fatality rate of this virus was estimated 
to be 2% but ranged in some countries from 4 to 9%. After 
adjustment for asymptomatic cases, this virus’s actual 
fatality rate was estimated to be around 1%. The major 
challenge of COVID-19 is the rapid transmission of the 
virus and the substantial proportion of asymptomatic indi-
viduals who accounted for 40-50% of transmission.3
Extensive efforts are being made to fight this virus, 
including both pharmacological and non-pharmacological 
interventions. In the search for potential pharmacologic 
agents that might be useful to protect against the virus 
and/or treat COVID-19 patients, clinicians have reposi-
tioned chloroquine (CQ) and hydroxychloroquine (HCQ) 
as a treatment regimen.3 The rationale for selecting this 
regimen in the early months of the pandemic was the 
following: (1) This regimen has been previously utilized 
for the cure against SARS-CoV-1 with documented suc-
cess, and (2) recent in vitro experiments in China showed 
that these agents could inhibit viral replication in vitro.3
Since then, this regimen has divided the world with one 
extreme trolling it as “game changer in medicine” while 
other touting it as ‘useless and dangerous’. Therefore, in 
the present article, we provide a comprehensive review of 
the use of CQ/HCQ regimen with or without azithromycin, 
illustrating the structure, mechanism of action, side effects 
and drug interactions, and experimental studies data, and 
data of clinical trials.
Structure of the SARS-CoV-2 Virus
Coronaviruses are spherical with an average diameter of 
80-120 nm. They possess a number of club-shaped (17-20 
nm) glycoproteins spikes projecting from the surface of 
the viral envelope.4 The virus particle contains five major 
structural proteins, which are glycoprotein spikes (S), an 
envelope protein (E), matrix protein (M), and nucleocapsid 
(N) protein.4 The glycoprotein spikes mediate virus’s 
attachment to different host cell receptors, depending 
upon the receptor-binding domain (RBD). On attachment 
to the host cell receptor, the glycoprotein spikes S protein 
cleavages into two subunits, namely, N-terminal S1 and 
C-terminal S2 subunit regions by the host proteases 
enzyme.4 S1 subunit contains a signal peptide and 
a RBD. Meanwhile, S2 subunit contains conserved fusion 
peptide (FP), heptad repeat (HR) peptides, transmembrane 
domain (TM), and a cytoplasmic domain.4
The S1 subunit of SARS-CoV-2 showed 70% identity 
to Beta coronavirus’s S1 subunits (SARS-CoV-1) isolated 
from human and bats.5 Human angiotensin-converting 
enzyme 2 (hACE2) acts as the key receptor to infect the 
human cells.5 The S2 subunit plays an important role in 
mediating the virus fusion and entry into the host cell, in 
which heptad repeat 1 and 2 (HR1, HR2) can interact with 
six helical bundles, thereby bringing the viral and cellular 
membrane in close proximity for fusion.5
The ACE2-binding affinity of RBD in S1 subunit of 
SARS-CoV-2 is 10 to 20-fold higher, which might con-
tribute to the higher infectivity and transmissibility of 
SARS-CoV-2 compared to SARS-CoV-1.5 The 
M glycoprotein is pre–glycosylated M polypeptides with 
a size range of 25–30 kDa (221–262 amino acids) and 
gives shape to the virus envelope.5 Envelope protein (E) is 
a small polypeptide with a size range of 8.4–12 kDa (76- 
109 amino acids) and is the integral membrane protein.4,5
Chemical Compositions and Sources of 
CQ and HCQ
CQ and HCQ have similar chemical structures and cellular 
mechanisms of action.3 CQ is administered as a phosphate 
salt, whereas HCQ is administered as a sulfate. Both drugs 
are absorbed in the upper intestinal tract.6 The CQ is 
produced by systematic modification of quinine, which is 
a plant alkaloid and quinoline containing compound.7 
Hans Andersag discovered CQ in 1934 at the Bayer 
laboratory and named it “Resochin”. It became available 
in clinical practice in 1947 and quickly became the drug of 
choice for the treatment of malaria.7
CQ, 7-chloro-4-(4-diethylamino-1-methylbutylamino)- 
quinoline is made by reacting 4-diethylamino-1-methylbuty-
lamine with 4, 7-dichloroquinoline at 180°C.8 Each of the 
two components involved in CQ synthesis can be prepared in 
several ways (Figure 1). In 1946, HCQ sulfate was synthe-
sized as a derivative of CQ by incorporating a hydroxyl 
group into CQ, and they both share comparable mechanisms 
of action as weak bases and immuno-modulators.3
It was proved that CQ is two to three times as toxic in 
animals as HCQ.9 More interestingly, HCQ, compared with 
CQ, is vastly available to cure auto-immune diseases like 
rheumatoid arthritis and systemic lupus erythematosus.10
Mechanism of Action of CQ and HCQ
Both CQ and HCQ are weak bases that increase the pH of 
acidic intracellular organelles like lysosomes/endosomes 
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that require low pH for maturation and function.11 CQ 
showed elevation in pH of lysosomes from nearly 4.5 to 
6.5 at 100 μM. However, the effect of HCQ on pH values 
of lysosomes/endosomes is not known due to the lack of 
studies in this regard.3
Moreover, CQ was found to cause changes in the glyco-
sylation of ACE2 spike protein and receptor that ultimately 
inhibits the entry step and the post-entry phase of SARS-CoV 
-2.12 HCQ in the time-of-addition experiment showed its 
ability to exert the same mechanism (Figure 2).
In addition to the previously known mechanism, 
a novel mechanism of action for CQ and HCQ on 
COVID-19 was discovered in 2020 by Fantini et al13 as 
it is known that SARS-CoV-2 starts its replication by 
attaching to the spike (S) viral protein of respiratory 
cells.13 The S protein utilizes sialic acids and ACE-2 
receptor connected to host cell surface gangliosides for 
entry. The study showed that CQ (or its more active 
derivative, HCQ) has a high affinity for binding to gang-
liosides and sialic acids.13
The study also distinguished a novel ganglioside- 
binding domain (111–158) at the tip of the N-terminal 
domain of the SARS-CoV-2 S protein. It is expected that 
this domain can ease attachment with the ACE-2 receptor 
and enhance contact of the virus to lipid rafts.13
Side Effects of the CQ/HCQ Treatment
High doses of CQ were found to cause severe side effects, 
but it was reported that CQ in a prescribed dose exerts 
relatively few adverse effects.14 Ocular adverse effects 
such as long and subtle symptoms of reduced visual acuity, 
diplopia, retinal toxicity, and bilateral loss of vision were 
found to be the most severe side effects caused by high 
doses of CQ.15 A high dosage of CQ also causes critical 
psychiatric issues such as hallucinations, paranoia, and 
suicidal ideations.16 Injecting CQ intramuscularly has 
shown to cause potentially life-threatening hypotension.17
Other adverse effects include pruritus, photosensitivity, 
seizures, paranoia, hallucinations, and retinopathy charac-
terized by the inability to focus on near and far objects18 
(Figure 3). HCQ has a more solubility and less toxic 
metabolites compared with CQ. Hence, it has fewer 
adverse effects and is relatively safer.19 For these reasons, 
HCQ is often preferred over CQ where possible.18
HydroxychloroquineChloroquine
37.1.1.1 37.1.1.2 37.1.1.3           
Figure 1 Chemical composition of chloroquine and hydroxychloroquine.
Therapeutics and Clinical Risk Management 2021:17                                                                           http://doi.org/10.2147/TCRM.S301817                                                                                                                                                                                                                       
DovePress                                                                                                                         
373







































































Powered by TCPDF (www.tcpdf.org)
Cautions and Contraindications
Patients receiving CQ or/and HCQ must be monitored 
for their haematological parameters (RBC, WBC, and 
platelet counts), blood glucose (hypoglycemic risk of 
HCQ), serum electrolytes, renal as well as hepatic 
functions.20 Electrocardiography (ECG) is essential 
before starting therapy with these medications and the 
concomitant use of these drugs with other drugs known 
to extend the corrected QT (QTc) interval of the heart 
(like antihistamines, anti-depressants, anti-arrhythmic, 
anti-psychotics, moxifloxacin, teneligliptin, and ondan-
setron) should be averted.21 The addendum of HCQ to 
azithromycin, as reported by Gautret et al22 in the 
French trial, may elevate QTc extension.23 If QTc is 
450–500 msec, it is recommended to do daily ECG. 
CQ and HCQ must not be utilized simultaneously with 
ritonavir/lopinavir and remdisivir for expected QTc 
extension. Additionally, hypoglycaemia should be 
observed in diabetes patients, particularly with conco-
mitant usage of CQ/HCQ and ritonavir/lopinavir.23 
Pharmacovigilance on the mental and visual disorder is 
also carefully wanted (Figure 4).
Despite case reports of reversible heart failure and CQ- 
induced cardiomyopathy in the literature, large meta- 
analysis and numerous investigations carried out in 
patients having rheumatoid arthritis confirmed a lowered 
cardiovascular hazard with both drugs; nonetheless, 
a baseline ECG must be completed in patients with certain 
cardiovascular disease.24 Every clinician utilizing these 
drugs should realize contraindications to both compounds; 
porphyria, pre-existing maculopathy, retinopathy, glucose- 
6-phosphate dehydrogenase deficiency, epilepsy, recent 
myocardial infarction, hypersensitivity to these agents, 
and QTc>500 msec.20 There is no evidence that CQ and 
HCQ are contraindicated in lactating and pregnant 
women.25
It is worth noticing that CQ and HCQ interact with 
various drugs; many lead to QT prolongation and might 
lead to serious cardiac events and death. As mentioned 
earlier, this includes patients who take the CQ/HCQ 
Figure 2 The possible mode of action of chloroquine and hydroxychloroquine versus SARS-CoV-2 infection: (1) interference with the terminal glycosylation of cellular 
receptor angiotensin-converting enzyme 2 (ACE-2) leads to obstructing virus-receptor attachment; (2) increasing the pH of acidic cellular organelles lead to prevention of 
endocytosis with adverse influences on post-translational modification of recently synthesized viral RNA and virion transport; (3) blocking of viral protein synthesis and 
virion assembly.
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regimen with azithromycin. Such patients require close 
cardiac monitoring as long as they are on the CQ/HCQ 
regimen.23 Besides, CQ/HCQ might decrease blood 
glucose; therefore, these drugs can be used with caution 
in patients with diabetes mellitus. A recent study showed 
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Figure 3 The possible side effects of chloroquine and hydroxychloroquine.
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Figure 4 Cautions and contraindications during treatment with chloroquine (CQ) and hydroxychloroquine (HCQ).
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hypoglycaemic events.26 A summary of the common drug 
and disease interactions of CQ and HCQ are shown in 
(Table 1).
Methods of Selecting Studies for This 
Review
We searched PubMed, SCOPUS, and Web of Science until 
December 31, 2020, using the keywords “(chloroquine OR 
hydroxychloroquine) and (COVID-19 OR SARS-CoV-2 
OR 2019-nCOV)”. Studies were screened for eligibility 
for this review. Studies meeting the following conditions 
were reviewed (1) study design: experimental animal stu-
dies and prospective clinical trials, (2) study drug: chlor-
oquine and hydroxychloroquine, (3) outcomes: viral 
inhibition in experimental studies and mortality or time 
to recovery in clinical trials. Studies that do not satisfy 
these criteria were excluded from the review. Eligible 
studies were presented in tables and narratively discussed 
in the text.
Experimental Studies
The continuous and rapid spread of the COVID-19 
pandemic has led to extensive ongoing efforts 
worldwide to develop effective and safe therapy. CQ 
and HCQ in COVID-19 are among the drugs being 
tested, which were reported on February 4, 2020, to 
suppress SARS-CoV-2 in vitro. There is considerable 
in vitro evidence that CQ and HCQ are efficient in 
preventing SARS-CoV-2 vigour. Liu et al3 detected 
that both drugs have a 50% cytotoxic concentration 
(CC50). However, the 50% maximum efficient concen-
tration was lower for CQ than HCQ (EC50 – the dose at 
which viral RNA elevation is suppressed by 50%) 
regardless of the multiplicity of infection (MOI – the 
ratio of virions to host cells).3
Wang et al27 found that CQ has in vitro antiviral vigour 
with an EC50 of 1.13 μM and CC50 >100 μM at an MOI 
of 0.05 and shown that the eclecticism for SARS-CoV-2 is 
high compared with that for host cells. The study also 
showed that CQ at a concentration of 0.36 mg/L decreased 
viral load by 50% in vitro using Vero E6 cells.27
Yao et al28 also proved the activity of CQ versus 
SARS-CoV-2 and detected that CQ was less potent than 
HCQ in vitro versus SARS-CoV-2 (EC50 of 5.47 μM and 
0.72 μM, respectively, MOI = 0.01). Based on physiologi-
cally based pharmacokinetic (PBPK) model results, oral 
HCQ sulfate with a supplying dose of 400 mg twice a day 
then 200 mg twice a day as a maintenance dose for four 
days is advised for SARS-CoV-2 infection, and it is three 
times more potent than CQ phosphate when given 500 mg 
twice per day for five days in advance.28
Clinical Trials on CQ/HCQ Regimen for 
the Protection Against SARS-CoV-2 
Infection
Although preclinical evidence suggests that CQ and HCQ 
can inhibit viral replication and might prevent COVID-19, 
the current evidence does not support their prophylaxis 
efficacy against SARS-CoV-2 infection.27
Expert opinions advised using the CQ/HCQ regimen 
for prophylaxis against SARS-CoV-2 infection, particu-
larly between healthcare laborers who are at higher hazard 
of infection.29,30 However, this opinion was refuted by 
data from a well-designed randomized controlled trial on 
821 participants. Participants were allocated to be admini-
strated with either HCQ or placebo within four days after 
exposure. The happening of novel symptoms compatible 
with COVID-19 did not vary markedly among the two 
groups (11.8% versus 14.3%; P=0.35).31
Table 1 The Commonest Drug Interactions and Disease 
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Clinical Experiments on CQ/HCQ 
Regimen for the Therapy of COVID-19
Recent literature has suggested that CQ/HCQ drugs could 
be used as antiviral drugs to cure COVID-19 infections.24 
In addition, Iyer et al32 stipulated that the CQ can block 
the quinone reductase-2, a fundamental agent needed for 
the sialic acid biosynthesis that SARS-CoV-2 utilizes it 
as the receptor moieties. A recent small clinical study by 
Gautret et al22 reported that positive SARS-CoV-2 in 
nasopharyngeal secretions significantly decreased on day 
six after inclusion in HCQ-treated COVID-19 patients 
against patients who received supportive care only.22 The 
CQ elevates pH in host cell lysosomes and passively 
affects virus–receptor linking and intervenes with the gly-
cosylation of SARS-CoV-2 receptors. Additionally, it 
showed a hopeful antiviral influence versus SARS-CoV-2 
in vitro and limited the course of the disease and enhanced 
COVID-19-pneumonia patients.33
The first evidence of CQ effectiveness in COVID-19 
came from China in February 2020 by the Chinese 
government.34 These data reported that CQ phosphate 
was given to over 100 patients in China and reduced the 
duration of illness and significantly improved pneumonia 
infection and lung imaging. There were no adverse events 
reported. It seems that combining data from various in- 
progress trials using a variety of study designs released 
such findings. A study by Gautret et al22 in France on 
March 17, 2020, considered as the first clinical trial, was 
conducted as an open-label non-randomized controlled 
experiment.22 The trial included patients who suffered 
from SARS-CoV-2 among which 22 of the 36 patients 
included in the study had symptoms in the upper respira-
tory tract, eight had symptoms in the lower respiratory 
tract, while six patients were asymptomatic.22 The experi-
mental group (22 patients) was treated with HCQ 200 mg 
three times per day for ten days, whereas the control group 
was treated with ordinary care.22 Azithromycin was also 
prescribed for six patients of the treatment group to pre-
vent bacterial superinfection. In this trial, SARS-CoV-2 
carriage at day 6 was the primary outcome which was 
examined by testing nasopharyngeal swabs utilizing PCR 
of SARS-CoV-2 RNA.22
The experiment’s outcomes revealed that the experi-
mental group was markedly tested negative for the virus 
than patients in the control group (70% vs. 12.5% virolo-
gically cured, P<0.001) on day 6. Furthermore, the results 
of HCQ and azithromycin combination were astonishing 
as all patients treated with this combination were negative 
on day 6. The study proved the efficiency of HCQ and the 
possible synergistic influence of its combination with azi-
thromycin needs further declaration, as suggested by 
Gautret et al.22
Despite this trial’s favourable outcomes, severe limita-
tions have made its results questionable.35 First, there was 
recruitment for an additional six patients but were 
excluded, and no intention-to-treat analysis was performed 
due to many reasons that have led to the failure of follow-
ing-up these patients.35,36 Secondly, the researchers added 
that the sample size was not enough to achieve 85% 
power, which required recruiting 48 patients for the 
required power to be achieved. The overstatement of 
influence sizes and false-positive outcomes can be 
expected from the underpowered trial with a sample size 
of 36 patients.37 On the sixth day, the researchers reported 
that a patient showed negative for the virus but revealed 
positive on the eighth day, which raised a concern about 
a trial lacking for long-term and medium follow-up data 
since the primary outcome is viral PCR status at day 6.37 
This incidence indicates that long-term data of CQ/HCQ 
effectiveness in the therapy of COVID-19 is necessary. 
Finally, the trial’s allocation bias cannot be denied where 
there was no randomization for patients to the control and 
treatment groups.37
Another pilot study published on March 25, 2020, by 
Chen et al38 who evaluated the safety and efficacy of HCQ 
in the management of patients with COVID-19. A sum of 
30 patients diagnosed with COVID-19 was recruited and 
randomly allocated (1:1) into the treatment and control 
groups. The test group treated with oral CQ sulfate 
(400 mg one time a day for five days) based on conven-
tional treatment, while the control group received tradi-
tional treatment.38 The principal outcome was the negative 
change rate of COVID-19 nucleic acid in respiratory phar-
yngeal swab on the seventh day. On day 7, the test group’s 
throat swabs showed negative COVID-19 nucleic acid in 
13 patients (86.7%), with one case progressed to severe 
during the treatment.38 In comparison to the treatment 
group, 14 (93.3%) subjects in the control group (P>0.05) 
also tested negative. The average period between virus 
nucleic acid negative maintenance and patients’ hospitali-
zation in the test and control groups was 4 (1–9) days and 
2 (1-4) days, respectively (U=83.5, P>0.05).38 In terms of 
safety, abnormal liver function and transient diarrhea in the 
experimental and the control groups subjects were noticed 
in 4 (26.7%) and 3 (20%) cases, respectively (P>0.05). 
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The small sample size in this study has made a general 
conclusion that the prediction of typical COVID-19 
patients is perfect.38
Following that, an extensive argument was raised 
against Gautret et al22 study by Kim et al.39 It was reported 
that there was a rush in judgment of the study due to the 
pressing requirement for efficient therapy for SARS-CoV 
-2. The clinical trial’s limitations were discussed, such as 
using an invalidated replacement endpoint, deficiency of 
blinding or randomization, and including the small sample 
size. Another study highlighted methodological flaws that 
were considered to impact the validity of the findings.40
Despite the limitations in the first clinical trial, its 
promising results ended up advising the usage of CQ/ 
HCQ in the management of COVID-19 officially by 
guidelines. The National Health Commission published 
the recommendation of treatment COVID-19 by CQ, 
China, published in mid-February 2020, indicating that 
500 mg CQ phosphate (equivalent to 300 mg CQ) twice 
per day for ten days is recommended for patients with 
COVID-19.41 On March 17, 2020, other recommendations 
published by the L. Spallanzani National Institute for 
Infectious Disease in Italy, in which the combination of 
CQ (500 mg CQ per day) or HCQ (200-500 mg HCQ per 
day) with a different antiviral drug is indicated for 
COVID-19.42
A pharmacokinetic study in France aimed to optimize 
HCQ dosing in the intensive care unit (ICU) of COVID-19 
patients was carried out by Perinel et al.43 The study 
recruited 13 patients in ICU who were treated by HCQ 
at a dose of 200 mg twice per day. The mean age of 
patients was 68 years, 31% with moderate or severe 
renal failure, and 46% were obese.43 The study demon-
strated that the dosing regimen of 200 mg thrice a day is 
inappropriate to reach a supposed target blood level of 1– 
2 mg/L in this population. According to data from patients 
with rheumatoid arthritis and the 161 blood levels regis-
tered, the proposed dosing regimen delivers a dose of 
800 mg once per day on the first day, then 200 mg twice 
per day for seven days.43
The efficacy of combining azithromycin and HCQ was 
also evaluated by an uncontrolled non-comparative obser-
vational study carried out by Gautret et al22 in 80 patients 
diagnosed with a relatively mild infection of COVID-19. 
Six days were set as the minimum follow-up period. There 
was a clinically marked amelioration in all patients, except 
for one patient aged 86 years who died, and another 
patient (74-year-old) was still in the ICU. The viral load 
of nasopharyngeal samples rapidly decreased. Of these 
samples, 83% of the patients were tested negative on the 
seventh day, while on the eight’s day, 93% were 
negative.22 On day 5 of the treatment, respiratory samples’ 
viral cultures were found negative in 97.5% of the 
patients.22 Therefore, patients were quickly got out of the 
infectious disease unit with five days as an average length 
of stay. Although the number of patients was just 80 and 
the severity of the illness was mild, the study reflected an 
excellent picture of the combination of azithromycin and 
HCQ.22
Regarding the optimal dose of HCQ in COVID-19 
patients, Garcia-Cremades et al44 tested the safe and effec-
tive dosage of HCQ for COVID-19 treatment. It was 
predicted that doses of over 400 mg twice a day of HCQ 
for ≥5 days reduced viral loads quickly, shortening the 
treatment course, decreasing the number of patients with 
detectable SARS-CoV-2 infection.44 In contrast, increas-
ing the dose of HCQ to over 600 mg twice a day has more 
probability of prolonging QTc intervals.44 In recent study 
from Belgium, Catteau et al45 have shown that the low 
dose HCQ monotherapy has reduced mortality rate com-
pared with the non-HCQ treated patients.45
A study from South Korea by Lee et al46 investigated 
the effectiveness of post-exposure prophylaxis after 
a significant exposure of COVID-19 in a long-term care 
hospital using HCQ (400 mg orally daily till the end of 14 
days of quarantine) in 211 persons containing 22 health-
care workers and 189 patients, with negative PCR checks 
for COVID-19.46 After completing the post-exposure pro-
phylaxis period by 184 patients and 21 care-workers with-
out any severe effects, all PCR tests were negative at the 
ending of the 14 days of quarantine.46 The shortage of 
control groups in the study and having other 29 hospital 
staff who tested negative after the 14 days of quarantine 
although they did not receive post-exposure prophylaxis 
(Although being classified low-risk exposure) are consid-
ered essential limitations in the study.46 In a study high-
lighted COVID-19 and immunomodulation in 
inflammatory bowel diseases (IBD), Neurath47 mentioned 
that there is a possibility for drug–drug interactions 
between HCQ or IBD therapies. The risk of interaction is 
potentially increased by combination of medication with 
HCQ and infliximab/adalimumab for nerve harm.47
However, there is no evidence to discontinue IBD- 
specific medications in COVID-19 patients cured with 
such drugs. The favourable effect of HCQ and azithromy-
cin combination on the clinical results and viral loads of 
http://doi.org/10.2147/TCRM.S301817                                                                                                                                                                                                                                 
DovePress                                                                                                                                
Therapeutics and Clinical Risk Management 2021:17 378







































































Powered by TCPDF (www.tcpdf.org)
patients infected with COVID-19 has led to implementing 
the regimen by clinicians worldwide.48 On the other hand, 
both drugs have been independently revealed to influence 
the electrical system of the heart, causing QT-interval 
elongation, drug-induced torsades de pointes, and drug- 
stimulated sudden cardiac death.48
In this context, an American study carried out by 
Chorin et al49 examined the QT-interval in 84 patients 
with COVID-19 cured with a combination of HCQ 
(400 mg daily on day one, then 200 mg daily from day 2 
to 5) and azithromycin (500 mg per day for five days). 
After 4.3 ± 1.7 days as an average time for exposure to 
HCQ/azithromycin, ECG was followed up.49 It was found 
that the QTc markedly extended. In a group of nine (11%) 
of those patients, there was a severe prolongation of the 
QTc to >500 ms, which is a marker of a high danger of 
sudden cardiac death caused by malignant arrhythmia.49 
Out of the group of nine patients, five patients had 
a normal QTc. It was suggested that regular evaluation 
for QTc must be implemented by patients with COVID-19 
who are cured with a combination of HCQ/azithromycin 
combination, especially those who have comorbidities or/ 
and with other QT-prolonging medications.49
A randomized clinical experiment by Borba et al50 
from Brazil compared the effect of high doses (600 mg 
twice per day for ten days) against small doses (450 mg 
twice a day on day one and OD for four days) of CQ 
diphosphate as adjunctive therapy for 81 adult patients 
treated with SARS-CoV-2 infection.50 Forty patients 
received low doses, while 41 received high doses. In the 
small dose group, 15.0% (6 out of 40) of patients died 
on day 13 days compared with 39% of the high-dose group 
(16 of the 41 patients). Regarding safety, 4 of 36 patients 
(11.1%) receiving low-dose experienced prolongation of 
QTc interval compared with 7 of 37 (18.9%) patients 
receiving the high-dose.50 Besides, ventricular tachycardia 
was developed in 2 patients (2.7%) in the high-dose group. 
As a result of these findings, the trial was stopped. It was 
inferred that the high dosage of CQ must not be advised 
for adversely ill patients with COVID-19.50
Patients with systemic lupus erythematosus (SLE) were 
a population of interest for Mathian et al.51 SARS-CoV-2 
represents a source of concern for the management of 
patients with SLE. In patients with SLE, the use of immu-
nosuppressive drugs, the intrinsic perturbations of the 
immune response, and the potential presence of organ 
damage associated with their disease make those patients 
at higher risk of severe infections. Currently, and as a part 
of SLE treatment, HCQ is a standard long-term drug for 
SLE.52
HCQ also has antiviral activity in COVID-19, and its 
therapeutic or even prophylactic activity for COVID-19 
was proved by preliminary clinical trials. Mathian et al51 
examined the clinical observations of COVID-19 in 
a series of 17 patients with SLE receiving long-term treat-
ment of HCQ (median of 7.5 years) and with obesity and 
chronic kidney disease as comorbidities.51 Although this 
study gave an initial clinical view of the infection course 
in patients with SLE cured with HCQ, it did not conclude 
the severity and incidence rate of COVID-19 in SLE. 
Moreover, it was also shown that HCQ does not protect 
against COVID-19, at least its negative practice, in 
patients with SLE.51
On the other hand, strong evidence from a well- 
designed randomized controlled trial (RCT) does not 
advocate the usage of CQ/HCQ regimens in COVID-19 
patients. Data from the UK’s recovery trial, the world’s 
largest COVID-19 clinical trial to date, by Horby and 
Landray53 showed that HCQ did not reduce the 28-day 
mortality rate among COVID-19 patients compared to the 
standard of care.53 While these outcomes were questioned 
by several experts owing to the relatively higher loading 
dose.
On the first day of the study (2400 mg in 24 hours), 
similar findings were reached by the WHO’s solidarity 
trial in several countries worldwide. On June 5, 2020, the 
WHO announced that based on an interim analysis of the 
trial data, HCQ did not reduce the mortality compared to 
the standard of care.54 The characteristics of the in vitro 
studies on SARS-CoV-2 and clinical trials studying the 
efficacy of CQ and HCQ in COVID-19 patients are illu-
strated in Table 2.
Past Experiences, Current Situations, and 
Future Directions
Based on the review of the existing literature, the CQ/ 
HCQ regimen gained worldwide attention. It showed 
a promise in the preclinical experiments and some clinical 
studies during the early months of the pandemic. 
Nonetheless, the usage of the CQ/HCQ regimen in treating 
COVID-19 has been challenged by the recent data from 
well-designed RCTs. The CQ and HCQ are widely used 
for the first-line of treatment against the malarial parasite 
in most endemic Asia and African countries.63 Besides 
malaria treatment, CQ is utilized in rheumatoid arthritis, 
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Table 2 Characteristics of the in vitro Investigations on SARS-CoV-2 and Clinical Trials Studying the Efficacy of Chloroquine and 





Intervention and Comparison 
Groups
Primary Outcomes
China28 in vitro study with SARS-CoV-2-infected 
Vero cells
Infected Vero cells were treated with CQ 
or HCQ at 0.032, 0.16, 0.80, 4, 20, or 
100 μM for 24 or 48 h.
● CQ and HCQ decreased viral replication 
in a concentration-dependent manner.
● EC50 values for CQ were 23.90 and 5.47 
μM at 24 and 48 h, respectively.
● EC50 values for HCQ were 6.14 and 
0.72 μM at 24 and 48 h, respectively.
China28 in vitro study with Vero cells Vero cells were pre-treated CQ or HCQ 
at 0.032, 0.16, 0.80, 4, 20, or 100 μM for 
two h and were then infected with SARS- 
CoV-2 and incubated for 24 or 48 h.
● HCQ showed a higher in vitro antiviral 
influence in comparison with CQ.
● The EC50 values for CQ were greater 
than 100 and 18.01 μM at 24 and 48 h, 
respectively.
● EC50 values for HCQ were 6.25 and 
5.85 μM at 24 and 48 h, respectively.
China3 in vitro study with African green monkey 
kidney VeroE6 cells
SARS-CoV-2 infected cells at four 
different multiplicities of infection (MOI) 
and treated with CQ or HCQ up to 50 
μM for 48 h
● CC50 values of CQ and HCQ were 273 
and 250 μM, respectively, which are not 
significantly different.
● At all MOI (0.01, 0.02, 0.2, and 0.8), EC50 
for HCQ (4.51, 4.06, 17.31, and 12.96  
μM) was higher than that of CQ (2.71, 
3.81, 7.14, and 7.36 μM).
● Statistically, the variations in EC50 values 
were significant at MOI of 0.01 (P < 0.05) 
and 0.2 (P < 0.001).
China27 in vitro study with Vero E6 cells. Cells were infected with SARS-CoV-2 at 
MOI of 0.05 in the presence of different 
concentrations of CQ, penciclovir, 
ribavirin, nafamostat, nitazoxanide, 
remdesivir, favipiravir and chloroquine.
● EC50, SI index, and CC50 values for CQ 
were 1.13 μM, >100 μM, and 88.5.
● These values were higher for for ribavirin 
(EC50 = 110 μM, CC50> 400 μM, and  SI >  
3.65), penciclovir (EC50 = 96.0 μM, CC50  
> 400 μM, SI  > 4.17) and favipiravir (EC50  
= 61.9 μM, CC50 > 400 μM, SI  > 6.46), 
nafamostat (EC50 = 22.50 μM, CC50 > 100  
μM, SI  > 4.44), and was comparable to 
nitazoxanide (EC50 = 2.12 μM; CC50 >  
35.53 μM; SI > 16.76) and remdesivir  
(EC50 = 0.77 μM; CC50 > 100 μM; SI  >  
129.87) for EC50.
France22 Age >12 years and positive for SARS- 
CoV-2. Patients with HCQ or CQ allergy 
were excluded or had another 
recognized contraindication to cure with 
the drug. Pregnant and breastfeeding 
patients were excluded.
Oral HCQ 200 mg TD × ten days (n=20). 
Symptomatic treatment and AZT (n = 6; 
500 mg/d on day 1 then 250 mg/d for 
next 4 days) with HCQ. 
Patients (n=16) who rejected the cure or 
had relegation criteria, served as 
controls.
● Control patients were younger than HCQ- 
treated patients (37.3 years vs 51.2 years).
● At sixth day post-inclusion, 70% of HCQ- 
cured patients were negative compared 
with 12.5% in the control group (p= 0.001).
● At day six post-inclusion, 100% of patients 
treated with combination of HCQ and AZT 
were negative compared with 57.1% in 
patients cured with HCQ only, and 12.5% in 
the control group (p<0.001).
(Continued)
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Intervention and Comparison 
Groups
Primary Outcomes
China38 Confirmed COVID-19 patients. Thirty 
patients were randomly grouped into 
treatment and control groups.
Oral HCQ sulfate 400 mg OD × 5 days 
(n=15). 
No HCQ was provided to Patients 
(n=15).
● On day 7, the number of negative sam-
ples did not differ (13 (86.7%) cases in 
the HCQ group versus 14 (93.3%) cases 
in the control group; P>0.05)
● The period from hospitalization to nega-
tive result of virus nucleic acid did not 
differ (4±1.9 days in HCQ versus 2±1.4 
days in the control group; P>0.05).
● The time for body temperature normaliza-
tion was comparable (1±0.2 day I HCQ 
group versus 1±0.3 days in the control 
group).
● Radiological progress was noted on CT 
images in 7 cases (46.7%) of the control 
group and 5 cases (33.3%) of the HCQ 
group, and all patients revealed ameli-
oration in follow-up examinations.
● Three cases (20%) of the control group 
and four cases (26.7%) of the HCQ 
group had abnormal liver function and 
transient diarrhoea (P>0.05).
South Korea46 COVID-19 exposed individuals (211 
containing 22 careworkers and 189 
patients) with negative PCR tests for 
COVID-19 in a long-term care hospital in 
Korea. Four patients and one coworker 
were not finally completed.
COVID-19 exposed individuals were 
administered HCQ at 400 mg OD x 14 
days during the quarantine. 
No control groups.
● At the ending of two weeks of quarantine, 
all follow-up PCR tests were negative.
● A sum of 32 individuals (15.6%) men-
tioned one or more symptoms through 
post-exposure prophylaxis.
● The most common symptoms were skin 
rash (4.3%), loose stool or diarrhoea 
(9%), bradycardia (0.95%), and gastroin-
testinal upset (0.95%). Post-exposure 
prophylaxis was stopped in 5 patients 
(2.7%) because of the requirement for 
fasting (1), bradycardia (2), and gastro-
intestinal upset (2).
Netherlands55 Patients (n = 95) were aged 18 years or 
older and suspected of having COVID-19 
disease.
CQ was a loading dose of 600 mg 
followed by 300 mg BD (starting 12 
h after the loading dose), for the next 
four days
● CQ treatment in patients with COVID-19 
markedly extended the QTc interval by 
34–35 ms; 23% of the patients had a QTc 
interval exceeding 500 ms. Statistically 
marked influences were detected on QRS 
interval (mean difference 6 ms), PR inter-
val (mean difference 8 ms), and heart rate 
(mean difference –10 bpm).
(Continued)
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Intervention and Comparison 
Groups
Primary Outcomes
Netherlands23 A retrospective investigation of 251 
patients having COVID-19.
HCQ was orally administrated at 400 mg 
BD for one day (loading dose) then 
200 mg BD for four days. AZT was orally 
administrated for five days at a dose of 
500 mg OD.
● The QTc interval extended from 
a baseline of 439 ± 29 ms to a maximum 
value of 473 ± 36 ms (P < .001), which 
happen on day 4.1 ± 2 of treatment.
● Extreme novel QTc interval extension to 
>500 ms revealed in 23% of the patients.
● One patient showed polymorphic ventri-
cular tachycardia.
USA56 A retrospective investigation of 1376 
patients having COVID-19.
HCQ (n = 811) was provided at 600 mg 
BD on day 1, followed by 400 mg/d for 4 
next days. 
Control group patients were less 
adversely ill at baseline than those with 
HCQ-treated patients (n = 565; the ratio 
of the partial pressure of arterial oxygen 
to the fraction of inspired oxygen, 223 vs 
360).
● HCQ use was not accompanied with 
a markedly lower or higher hazard of 
death or intubation (hazard ratio, 1.04; 
95% CI, 0.82 to 1.32).
USA57 A retrospective investigation of 368 
patients diagnosed with COVID-19.
HCQ (n = 97) alone and HCQ + AZT (n 
= 113) in combination. 
In the control group (n = 158), no HCQ 
was provided.
● The hazard of death from any reason 
was elevated in the HCQ group 
(adjusted hazard ratio, 2.61; 95% CI, 1.10 
to 6.17; P=0.03).
● The risk of death was similar in the 
HCQ+AZ group (adjusted hazard ratio, 
1.14; 95% CI, 0.56 to 2.32; P=0.72).
● The hazard of ventilation was compar-
able in the HCQ group (adjusted 
hazard ratio, 1.43; 95% CI, 0.53 to 3.79; 
P=0.48) and the HC+AZ group (adjusted 
hazard ratio, 0.43; 95% CI, 0.16 to 1.12; 
P=0.09).
France58 A retrospective investigation of 181 
patients having COVID-19 and requiring 
oxygen ≥ 2 L/min.
HCQ (n = 84) 600 mg/d for 7 day 
In control (n = 97), no HCQ was 
provided.
● 20.2% of the patients in the HCQ group 
were died within seven days or moved 
to the ICU vs 22.1% in the no–HCQ 
group (16 vs 21 events, the relative 
hazard of 0.91, 95% CI 0.47-1.80) in the 
HCQ group.
● The death of 2.8% of the patients was 
within seven days vs 4.6% in the no– 
HCQ group (three vs four events, the 
relative risk of 0.61, 95% CI 0.13–2.89).
● 27.4% in the HCQ group versus 24.1% in 
control group patients developed acute 
respiratory distress syndrome within 
seven days (24 vs 23 events, relative risk 
of 1.14, 95% CI 0.65-2.00).
● 8 patients receiving HCQ (9.5%) 
revealed electrocardiogram modifica-
tions requesting HCQ stop.
(Continued)
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Intervention and Comparison 
Groups
Primary Outcomes
USA59 A retrospective investigation of 181 
patients having COVID-19.
HCQ at 200–600 mg OD/BD (n = 271) 
alone; 
HCQ + AZT (n = 735) in combination; 
AZT 200–500 mg once/OD/BD (n = 
211), and no drug (n =221)
● The death of patients treating with AZT 
alone, 21/211 (10.0% (95% CI, 5.9%- 
14.0%)), HCQ + AZT was 189/735 
(25.7% (95% CI, 22.3%-28.9%)), HCQ 
alone, 54/271 (19.9% (95% CI, 15.2%- 
24.7%)), and neither drug, 28/221 (12.7% 
(95% CI, 8.3%–17.1%)).
● Co marked variations in mortality for 
patients receiving HCQ + AZT (hazard 
ratio of 1.35 (95% CI, 0.76–2.40)), HCQ 
alone (hazard ratio of 1.08 (95% CI, 0.-
63–1.85)), or AZT alone (hazard ratio of 
0.56 (95% CI, 0.26–1.21)) in comparison 
with patients administrating neither 
drug.
● Cardiac arrest was markedly higher in 
patients receiving HCQ + AZT 
(adjusted OR, 2.13 (95% CI, 1.12–4.05)), 
but not HCQ alone (adjusted OR, 1.91 
(95% CI, 0.96–3.81)) or AZT alone 
(adjusted OR, 0.64 (95% CI, 0.27-1.56)) 
compared with patients receiving neither 
drug.
China60 A retrospective investigation of 181 
patients having COVID–19 and treated 
with HCQ.
HCQ 400 mg/d (200 mg BD) for 7–10 
days (n = 48). 
In the control group (n = 520), no HCQ 
was provided.
● Mortalities reduced in HCQ group 
(18.8% (9/48) versus 45.8% (238/520) in 
control group (p<0.001)).
● The time of hospitalization before 
patient death was 15 (10–21) days for 
the HCQ group versus 8 (4–14) days for 
control groups (p<0.05).
● The level of inflammatory cytokine IL–6 
markedly decreased from 22.2 (8.3–-
118.9) pg/mL to 5.2 (3.0-23.4) pg/ml 
(p<0.05) in the HCQ group, but there is 
no alteration in the control group.
Recovery trial 
UK61
An ongoing randomized controlled trial 
of more than 11,000 COVID-19 patients 
to date
HCQ(200 mg tablet containing 155 mg 
base equivalent) received a loading dose 
of four tablets (800 mg) at zero and six 
hours, then two tablets (400 mg) starting 
at twelve hours after the initial dose and 
then every twelve hours for the next nine 
days or until discharge.
● 28-day mortality was 26.8% and 25% in 
the HCQ and standard of care groups.
● HCQ treatment was markedly accompa-
nied with an elevated length of hospital 




An ongoing randomized controlled trial 




● Not Available; Details were not 
published.
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systemic and discoid lupus erythematosus, sarcoidosis, 
scleroderma, pemphigus porphyria cutanea tarda.63 
Despite drugs’ adverse effects on humans, such as cardiac, 
retinal, and neuromuscular toxicities, their benefits out-
weigh the toxicity effects.64,65 The CQ and HCQ have 
also been tested to treat various diseases such as human 
immunodeficiency diseases, Q fever, whipple disease, and 
fungal infection.65,66 These drugs have several 
other beneficial properties, including anti-inflammatory, 
immuno-modulating, anti-infective, anti-thrombotic, and 
anti-tumoral properties.65
Due to these multifaceted effects of CQ and HCQ, 
including antiviral properties, these drugs have been exten-
sively investigated against the SARS-COV-2 virus and 
COVID-19 patients, and the outcomes widely varied. 
Indeed, few in vitro investigations have revealed antiviral 
influences against SARS-COV-2.3,27,28 The results are pre-
liminary based on the small clinical trials and usually 
cofounding with pre-existing comorbidities, age, and 
severity of disease.51
The prophylaxis use of CQ and HCQ did not show any 
clinical efficacy in randomized controlled trials. In most 
cases, there is a lack of randomized control trials with long- 
term supervision of the patients and their contacts to explore 
the efficacy of CQ/HCQ for postexposure prophylaxis. 
Many times, its toxicity, particularly cardiac toxicities, out-
weighed its benefits, unlike the treatment of malarial infec-
tion. A recent meta-analysis of 12 studies showed no 
evidence of clinical benefit from CQ/HCQ administration 
in COVID-19 patients.35 Other limitations of this regimen 
were (1) the potential interaction with azithromycin and 
several other medications leading to QT prolongation and 
possible cardiovascular side effects and (2) the hypoglyce-
mia if not adequately monitored in diabetic patients. While 
close monitoring might optimize is regimen’s safety, the 
safety profile does not make it suitable for a pandemic 
situation. With several cases overwhelming the healthcare 
systems, it becomes unpractical to screen all patients for the 
potential interactions in the clinical setting. Future direc-
tions in the CQ/HCQ drugs might include improved drug 
delivery either by inhalation67 or transcatheter delivery 
through the bronchial artery.68
The randomized and controlled WHO Solidarity69 trial 
did not find an effectiveness of HCQ in reducing mortality 
rate (risk ratio of 1.19; P = 0.23) among the hospitalized 
COVID-19 patients. Based on lack of benefits of using 
HCQ, WHO54 and National Institute of Health had 
stopped trial for hospitalized COVID patients.61 A recent 
randomized controlled trial by Horby et al61 in the UK 
comprising 4716 COVID-19 patients showed that admin-
istration of HCQ had no benefits in decreasing death rate 
(rate ratio of 1.09; P = 0.15).
Moreover, a recent meta-analysis based on 28 rando-
mized trial containing 10.012 COVID-19 patients treated 
with HCQ, 307 patients with CQ and 63 patients with both 
CQ and HCQ in which WHO Solidarity69 and 
RECOVERY61 included that HCQ treatment was asso-
ciated with increased (risk ratio of 1.11; P = 0.02) mortal-
ity rate, whereas CQ did not show (risk ratio of 1.77; P = 
0.21) any benefit in reducing mortality rate.70 Finally, 
according to new data from two large RCTs (Recovery 
and Solidarity), the United States Food and Drug 
Administration (FDA) revoked the CQ/HCQ regimen’s 
emergency usage authorization in COVID-19 patients. 










An internet-based randomized controlled 
trial in non-hospitalized patients in the US 
and Canada
HCQ(800 mg once, followed by 600 mg 
in 6 to 8 hours, then 600 mg daily for 4 
more days) 
Placebo
● Symptom severity did not significantly 
differ over 14 days (−0.27 points (95% 
CI, −0.61 to 0.07 points); P=0.117).
● At 14 days, 24% of the participants 
receiving HCQ had ongoing symptoms 
compared with 30% receiving placebo 
(P=0.21).
● Medication adverse effects occurred in 
43% of HCQ group compared to 22% 
in the placebo group (P < 0.001).
Abbreviations: HCQ, hydroxychloroquine; CQ, chloroquine; OD, one a day; BD, twice a day; TD, thrice a day; CI, confidence interval; EC50, Half maximal effective 
concentration; CC50, 50% cytotoxic concentration. SI, selectivity index.
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The drugs are currently used for clinical trial purposes 
only.21 Furthermore, we searched clinicaltrials.gov for 
clinical trials on COVID-19 using the keywords: “chlor-
oquine OR hydroxychloroquine”. Then, we filtered the 
records to identify the “ongoing studies only”. The search 
retrieved 97 ongoing studies; the summary of the 97 
ongoing studies and their characteristics are provided in 
the Supplementary Table S1.
Conclusion and Recommendations
Based on the initial early experimental data of CQ and HCQ 
for treatment of SARS-CoV-2, the regimen received an 
emergency usage authorization from the FDA for COVID- 
19 on March 28, 2020. However, the two largest RCTs data 
to date showed no clinical advantage of HCQ treatment in 
COVID-19 patients. As a result, the FDA revoked the emer-
gency use authorization of this regimen. In terms of prophy-
laxis, one RCT showed no evidence of post-exposure 
prevention from COVID-19. Despite the initial promising 
findings in the in vitro studies and the widespread use of CQ/ 
HCQ in clinical settings during the 1st wave of COVID-19, 
current data from well-designed randomized controlled trials 
showed no evidence of benefit from CQ/HCQ supplementa-
tion for the treatment or prophylaxis against SARS-CoV-2 
infection. Particularly, the two largest randomized controlled 
trials to date (RECOVERY61 and WHO SOLIDARITY69), 
both confirmed that CQ/HCQ regimen does not provide any 
clinical benefit for COVID-19 patients. Therefore, we do not 
recommend the use of this regimen in COVID-19 patients 
outside the context of clinical trials.
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